Anjali D.

Anjali D. is an Executive Director at Iovance Biotherapeutics, Inc. Since joining in January 2020, Anjali leads the Product Development Team to advance an autologous cell therapy product through various stages. Prior to this role, Anjali held positions at Merck from 2016 to 2020, where Anjali contributed significantly to the development and approval of Keytruda for the treatment of squamous cell carcinoma of the esophagus. With a background in Clinical Research Design and Statistical Analysis, Anjali has also worked in project management roles at companies such as INC Research, Covance, and Montreal Heart Institute Coordinating Center. Their extensive experience in clinical science showcases their expertise in leading global trials and collaborating with various stakeholders in the healthcare industry.